Conference Coverage

VIDEO: Old, reliable drugs cut heart failure readmissions


 

At ACC 14

WASHINGTON, D.C. – Heart failure patients discharged on inexpensive, guideline-recommended drugs were half as likely to be readmitted for the condition within* 30 days, compared with those who weren’t given the drugs, according to a study of the Alabama Heart Failure Project that used Medicare data.

Dr. Kumar Sanam, an advanced heart failure fellow at the University of Alabama, Birmingham, presented the study at the annual meeting of the American College of Cardiology, and sat down with us to discuss the take-home implications of the study.

emechcatie@frontlinemedcom.com

*CORRECTION, 4/22/2014: An earlier version of this story misstated the follow-up period.

Recommended Reading

Latest heart failure guidelines break new ground
MDedge Cardiology
HFPEF’s diverse features pose management and trial challenges
MDedge Cardiology
Post-LVAD acute kidney injury is predictor of all-cause mortality
MDedge Cardiology
Physician/patient communication on ICDs deemed problematic
MDedge Cardiology
First guidelines on pulmonary hypertension in sickle cell disease released
MDedge Cardiology
MicroRNA MIR-25 found to play key role in heart failure
MDedge Cardiology
Higher MAP target fails to improve sepsis survival
MDedge Cardiology
What’s new in non-STEMI management
MDedge Cardiology
FDA panel rejects serelaxin approval for heart failure, but urges future study
MDedge Cardiology
Survival after TAVR superior to surgery in high-risk aortic stenosis patients
MDedge Cardiology